Evidence map›Paper›PMID 35680629›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Distribution and prognostic value of LymphGen genotyping in patients with diffuse large B-cell lymphoma].

F Zhang, Abulaiti Renaguli, X L Qi, Z Kou, S S Zhai, W Tan, Abuduer Muhebaier, Y L Nie, Y Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

F ZhangMedical School of Shihezi University, Shihezi 832001, China.
Abulaiti RenaguliDepartment of Haematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
X L QiDepartment of Haematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
Z KouDepartment of Haematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
S S ZhaiDepartment of Haematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
W TanDepartment of Haematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
Abuduer MuhebaierDepartment of Haematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
Y L NieDepartment of Haematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
Y LiDepartment of Haematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
People's Hospital of Xinjiang Uygur Autonomous Region · CNShihezi University · CN

Funding

Xinjiang Uygur Autonomous Region Regional Collaborative Innovation Special Fund 2020E0270
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Interleukin-1 Receptor-Like 1 ProteinLymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalGenotypeHumansPrognosisRetrospective StudiesInterleukin-1 Receptor-Like 1 ProteinDistributionLymphGen genotypingLymphoma, large B-cell, diffuseNext generation sequencingPrognosis

Identifiers

PMID35680629
PMCPMC9189491
OpenAlexW4282931770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.